Clinical Trial Update: Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 amyloid imaging and safety study of ACC-001 in subjects with mild to moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ACC-001

Snippet

Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED